INFINITY PHARMA

Active

Public limited companyfounded 197649 yrs activeVenecoweg 20A, 9810 Nazareth-De Pinte, BelgiumKBO/BCE: BE 0416.616.681

INFINITY PHARMA has been active since 1976 and the Belgian State Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €16.40M and a net result of €-231k. The figures fluctuate too strongly year-on-year for a reliable trend projection. Its solvency ranks better than 91% of 4812 sector peers (fiscal year 2025). The computed 12-month bankruptcy probability is 0.2% (very low).

Watch Print / PDF

Checked score

Score 2025

50 / 100

Fair▲ +12 vs 2024

The score combines four axes. Every signal that weighs is under Signals.

Axes · tick = 2024

Profitability5▲+5

Solvency88▲+9

Growth46▲+1

Stability100

Bankruptcy probability, 12 months

0.2% Very low

0%0.5%1.5%4%10%≥ 25%

Credit up to €800k at 30 days acceptable

Liquidity tight (current ratio 1.44 against 1.06 in 2024), and 12.8% of the assets are financed with debt.

How do we compute the score and the probability?

Credit advice for your own amount and term

Signals

Seven signals. The signal on the left, the evidence on the right.

−lowers risk+raises risk○neutral

Long track record

A company with a long track record statistically fails less often than a young one.

KBO · incorporation date

Age against the risk zone

Annual accounts: healthy financial profile

The latest annual accounts show a healthy profile in solvency, result and liquidity.

NBB · annual accounts 2025

Solvency, return and age of the figures

Solvency

87.2%

Return on assets

-1.2%

Age of the figures

8 mo

Lower-risk legal form

Companies with this legal form statistically fail less often than a BV.

KBO · legal form

Higher-failure-rate sector

In this sector companies fail more often than the Belgian average.

Gazette · bankruptcies per sector, NACE 46

Relative position

BE, all sectors

reference

Sector 46

higher

← fewer bankruptcies more bankruptcies →

Latest accounts filed on time

The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 11-06-2026, 50 days ahead of the deadline.

NBB · 10 filings

Deviation from the deadline

2025

50 d early

2024

46 d late

2023

54 d early

2022

56 d early

2021

61 d early

2020

67 d early

2019

61 d early

← before the deadline after the deadline →

The next deadline is still running

The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today.

Companies Code · seven months

Position in the running window

13-09-2026 today31-12-2026 close31-07-2027 deadline

No strike-offs in the KBO publications

We found no ex-officio strike-off or cessation. Our series starts in 2021 and has gaps, so this is not a confirmation that there is nothing.

KBO publications · our coverage

Financials · fiscal year 2025, full schema

Turnover

€10.74M▲ 0.6%

2024 · €10.68M

2018: €11.08M 2019: €10.63M 2020: €15.70M 2021: €10.25M 2022: €7.19M 2023: €11.38M 2024: €10.68M

2018 → 2025

EBIT margin

-0.7%▲ 4.3pp

2024 · -5.0%

2018: 16.7% 2019: 17.0% 2020: 14.0% 2021: -4.4% 2022: -0.8% 2023: -2.5% 2024: -5.0%

2018 → 2025

Net result

€-231k▲ 71.9%

2024 · €-823k

2018: €351k 2019: €13.33M 2020: €28.38M 2021: €-6.42M 2022: €-503k 2023: €-7.37M 2024: €-823k

2018 → 2025

Working capital

€1.06M▲ 425%

2024 · €201k

2018: €-48.21M 2019: €-41.81M 2020: €25.18M 2021: €25.77M 2022: €-7.15M 2023: €-14.10M 2024: €201k

2018 → 2025

Multi-year overview

Every figure with its change against the year before

▲ rise ▼ fall

Line20212022202320242025Trend

Turnover€10.25M-€7.19M▼ 29.8%€11.38M▲ 58.3%€10.68M▼ 6.2%€10.74M▲ 0.6%

Equity€31.32M-€5.82M▼ 81.4%€-1.55M€12.63M€16.40M▲ 29.8%

Operating result€-450k-€-54k▲ 88.0%€-286k▼ 427%€-531k▼ 85.7%€-73k▲ 86.3%

Net result€-6.42M-€-503k▲ 92.2%€-7.37M▼ 1,364%€-823k▲ 88.8%€-231k▲ 71.9%

Result per fiscal year

Operating resultNet result

The operating result stays negative: a loss of €73k in 2025 against €531k in 2024; the loss shrinks.

Balance-sheet composition

2025 in colour, 2024 as the grey bar beneath

Assets €18.81M

81.6%

18.4%

Fixed assets €15.35M▲ 23.4%

Current assets €3.46M▼ 2.1%

Equity and liabilities €18.81M

87.2%

12.8%

Equity €16.40M▲ 29.8%

Debt €2.41M▼ 27.8%

The debt ratio falls from 20.9% to 12.8%: equity grows while debt is paid down.

Key figures and ratios

2025 value · change against 2024

EBITDA

€19k▲

2024 · €-414k

Cash flow

€-140k▲

2024 · €-705k

Solvency

87.2%▲

2024 · 79.1%

Current ratio

1.44▲

2024 · 1.06

Quick ratio

0.41▲

2024 · 0.27

Debt / equity

0.15▼

2024 · 0.26

ROE

-1.4%▲

2024 · -6.5%

ROA

-1.2%▲

2024 · -5.2%

Interest coverage

0.35▲

2024 · -0.25

Debt

€2.41M▼

2024 · €3.34M

Debt ≤ 1 year

€2.41M▼

2024 · €3.34M

Income taxes

€3k▲

2024 · €-1k

Staff costs

€1.47M▼

2024 · €2.03M

Green means a favourable move, even when the figure itself falls: as with debt or debt / equity.

Filed annual accounts

As filed with the NBB · 2025 against 2024

Balance sheet Code20242025

Assets

Total assets20/58€15.97M€18.81M▲

Fixed assets21/28€12.43M€15.35M▲

Intangible fixed assets21€381k€296k▼

Tangible fixed assets22/27€43k€43k▼

Plant, machinery and equipment23€17k€19k▲

Furniture and vehicles24€5k€6k▲

Assets under construction and advance payments27€21k€18k▼

Financial fixed assets28€12.01M€15.01M▲

Affiliated companies280/1€12.01M€15.01M▲

Participating interests280€12.01M€15.01M▲

Other financial fixed assets284/8€3k€3k=

Amounts receivable and cash guarantees285/8€3k€3k=

Current assets29/58€3.54M€3.46M▼

Stocks and contracts in progress3€2.63M€2.49M▼

Stocks30/36€2.63M€2.49M▼

Raw materials and consumables30/31€822k€810k▼

Work in progress32€0-

Finished goods33€256k€520k▲

Goods purchased for resale34€1.55M€1.16M▼

Amounts receivable within one year40/41€729k€254k▼

Trade receivables40€570k€253k▼

Other amounts receivable41€159k€773▼

Current investments50/53€0€0=

Own shares50€0€0=

Cash at bank and in hand54/58€164k€688k▲

Deferred charges and accrued income490/1€15k€35k▲

Equity and liabilities

Total equity and liabilities10/49€15.97M€18.81M▲

Equity10/15€12.63M€16.40M▲

Contributions10/11€9.30M€13.30M▲

Capital10€9.30M€13.30M▲

Issued capital100€9.30M€13.30M▲

Reserves13€4.16M€3.33M▼

Non-distributable reserves130/1€1.29M€1.29M=

Legal reserve130€1.29M€1.29M=

Own shares acquired1312€0€0=

Tax-exempt reserves132€19k€19k=

Distributable reserves133€2.85M€2.03M▼

Profit (loss) carried forward14€-823k€-231k▲

Amounts payable17/49€3.34M€2.41M▼

Amounts payable within one year42/48€3.34M€2.41M▼

Financial debts43€0€0=

Other loans439€0€0=

Trade debts44€2.36M€2.22M▼

Suppliers440/4€2.36M€2.22M▼

Advances received on contracts in progress46€5k€5k=

Taxes, remuneration and social security45€322k€183k▼

Taxes450/3€152k€33k▼

Remuneration and social security454/9€169k€150k▼

Other amounts payable47/48€655k€104▼

Income statement Code20242025

Operating income70/76A€11.02M€11.29M▲

Turnover70€10.68M€10.74M▲

Change in stocks of work in progress, finished goods and contracts in progress71-€263k

Own construction capitalised72€0€18k▲

Other operating income74€344k€273k▼

Operating charges60/66A€11.56M€11.37M▼

Goods for resale, raw materials and consumables60€6.10M€6.34M▲

Purchases600/8€5.95M€5.82M▼

Change in stocks: decrease (increase)609€150k€523k▲

Services and other goods61€2.99M€3.48M▲

Remuneration, social security and pensions62€2.03M€1.47M▼

Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630€117k€92k▼

Write-downs on stocks, contracts in progress and trade receivables: additions (reversals)631/4€111k€-116k▼

Other operating charges640/8€17k€98k▲

Non-recurring operating charges66A€182k-

Operating profit (loss)9901€-531k€-73k▲

Financial income75/76B€1.49M€167k▼

Recurring financial income75€1.49M€167k▼

Income from current assets751€1.48M€773▼

Other financial income752/9€6k€166k▲

Non-recurring financial income76B€327€17▼

Financial charges65/66B€1.78M€323k▼

Recurring financial charges65€1.78M€323k▼

Debt charges650€1.67M€54k▼

Other financial charges652/9€107k€269k▲

Profit (loss) for the period before taxes9903€-824k€-228k▲

Income taxes67/77€-1k€3k▲

Taxes670/3-€3k

Tax adjustments and reversals of tax provisions77€1k-

Profit (loss) for the period9904€-823k€-231k▲

Profit (loss) for the period to be appropriated9905€-823k€-231k▲

Appropriation of the result

Profit (loss) to be appropriated9906€-823k€-1.05M▼

Profit (loss) brought forward from the previous period14P-€-823k

Transfer from equity791/2-€823k

From reserves792-€823k

Social balance

Average headcount (FTE)908719.813.6▼

The notes to these accounts (73 items: statements of assets and debts, cost breakdowns, rights and commitments) are not shown here.

Download as CSV

Timeline · acts, filings and financial milestones

All 71Financial 6Gazette 55Filings 10

Next filing, fiscal year 2026, expected by 31-07-2027

2026

07-07

State Gazette act Resignations & appointments

General meeting · Name change · Statutes amendment5 facts ▸

General meeting, 29/06/2026
Name change, Infinity Pharma
Statutes amendment
Director resignation, VERLINDEN Johan (bestuurder)
Power of attorney, bestuursorgaan, notaris/RVH-Notarissen, bedienden/aangestelden/lasthebbers

11-06

NBB filing Annual accounts filed

fiscal year 2025 · full schema

02-01

State Gazette act Capital & shares

General meeting · Capital increase · Bank account6 facts ▸

General meeting, 16-12-2025
Capital increase, €4.000.000
Bank account, 15-12-2025
Capital, €13.300.000
Power of attorney, Stijn RAES
Power of attorney, het bestuursorgaan

2025

31-12

State Gazette act Resignations & appointments

General meeting · Auditor appointment · Permanent representative4 facts ▸

General meeting, 06/10/2025
Auditor appointment, PwC Bedrijfsrevisoren BV (commissaris)
Permanent representative, Lien Winne (vaste vertegenwoordiger)
Mandate compensation, PwC Bedrijfsrevisoren BV

15-09

NBB filing Annual accounts filed

fiscal year 2024 · full schema · 46 days late

23-01

State Gazette act Capital & shares

General meeting · Capital increase · Bank account6 facts ▸

General meeting, 20/12/2024
Capital increase, €15.009.359,36
Bank account, 20/12/2024
Capital decrease, €7.368.329,98
Capital, €9.300.000
Power of attorney, Franck Cléty

2024

31-12

Financial Equity above €10MEq €12.63M

Equity rises from €-1.55M to €12.63M.

26-08

State Gazette act Resignations & appointments

General meeting · Director reappointment2 facts ▸

General meeting, 09/05/2023
Director reappointment, Padilla Rafael (bestuurder)

07-06

NBB filing Annual accounts filed

fiscal year 2023 · full schema

2023

31-12

Financial Weakest financial yearnet €-7.37M

Net result drops to €-7.37M, the lowest in the series; recovery starts the following year.

03-08

State Gazette act Restructuring

General meeting · Merger · Name change5 facts ▸

General meeting, 21/06/2023
Merger, 21/06/2023
Name change, PHARMA-PACK
Power of attorney, CLETY Franck
Power of attorney, William VAN LANCKER

05-06

NBB filing Annual accounts filed

fiscal year 2022 · full schema

03-05

State Gazette act Restructuring

Board meeting · Merger · Power of attorney7 facts ▸

Board meeting, 01/04/2023
Merger
Power of attorney, William Van Lancker
Power of attorney, Franck Cléty
Corporate purpose, De vennootschap heeft tot voorwerp: De studie, het onderzoek, het ontwerp, de analyse, de beschouwing, de farmacodynamie, de productie, de vervaardiging, de pro…
Corporate purpose, De vennootschap heeft als doel: productie, aan- en verkoop, in- en uitvoer, groot- en kleinhandel, verhuring, commissiehandel, vertegenwoordiging en consignatie…
Accounting effect, 01/01/2023

2022

22-12

State Gazette act Resignations & appointments

General meeting · Director appointment · Power of attorney4 facts ▸

General meeting, 11/05/2021
Director appointment, Johan Verlinden (bestuurder)
Director appointment, Céline Caveye (bestuurder)
Power of attorney, William Van Lancker

22-12

State Gazette act Resignations & appointments · Miscellaneous

General meeting · Approval · Director reappointment7 facts ▸

General meeting, 10/05/2022
Approval, jaarrekening afgesloten op 31 december 2021
Director reappointment, De Jong Cormelia Neeltje (bestuurder)
Auditor appointment, Deloitte Bedrijfsrevisoren CVBA (Commissaris)
Director discharge, INFINITY PHARMA
Director discharge, INFINITY PHARMA
Financial result, -6421844.19, EUR

31-05

NBB filing Annual accounts filed

fiscal year 2021 · full schema

2021

26-07

State Gazette act Capital & shares · Purpose · Statutes amendment · Restructuring

Merger · Name change · Statutes amendment8 facts ▸

Merger, met fusie door overneming gelijkgestelde verrichting
Name change, INFINITY PHARMA
Statutes amendment
Statutes amendment
Capital, €1.658.970,62
Corporate purpose, De studie, het onderzoek, het ontwerp, de analyse, de beschouwing, de farmacodynamie, de productie, de vervaardiging, de promotie, de verkoop, de handel, de ver…
Power of attorney, DELAMEILLEURE Tim
Power of attorney, CLETY Franck

25-05

NBB filing Annual accounts filed

fiscal year 2020 · full schema

21-05

State Gazette act Resignations & appointments

Director resignation · Director discharge · Director appointment5 facts ▸

Director resignation, Hernando Acosta (persoon belast met het dagelijks bestuur)
Director resignation, Bart Ameije (persoon belast met het dagelijks bestuur)
Director discharge, Hernando Acosta
Director discharge, Bart Ameije
Director appointment, Peter De Sutter (persoon belast met het dagelijks bestuur)

27-04

State Gazette act Restructuring · Miscellaneous

Board meeting · Power of attorney · Merger7 facts ▸

Board meeting, 01/04/2021
Power of attorney, Tim Delameilleure
Power of attorney, Franck Cléty
Merger
Accounting effect, 01/01/2021
Corporate purpose, De vennootschap heeft tot doel: de studie, het onderzoek, het ontwerp, de analyse, de beschouwing, de farmacodynamie, de productie, de vervaardiging, de promoti…
Corporate purpose, De vennootschap heeft tot voorwerp: 1) de handel onder al zijn vormen ... 2) de handel onder al zijn vormen van verbruiksartikelen ... 3) het fabriceren, het co…

2020

31-12

Financial Highest result since 2018net €28.38M ▲113%

Operating result €2.20M, net result €28.38M, both a record.

31-12

Financial Liquidity times 6current ratio 1.48

Current ratio from 0.26 to 1.48; short-term debt falls from €56.57M to €52.32M.

31-12

Financial Equity above €25MEq €37.74M ▲303%

3 profitable years in a row build equity to €37.74M.

19-11

State Gazette act Resignations & appointments

Board meeting · Director appointment2 facts ▸

Board meeting, 01/10/2020
Director appointment, Hernando Acosta (persoon belast met het dagelijks bestuur)

13-08

State Gazette act Capital & shares · Restructuring

Merger · Net-asset statement2 facts ▸

Merger
Net-asset statement, 31/12/2019

10-06

State Gazette act Restructuring

Board meeting · Merger · Power of attorney7 facts ▸

Board meeting, 28 mei 2020
Merger
Power of attorney, Tim Delameilleure
Power of attorney, Franck Cléty
Accounting effect, 1 januari 2020
Corporate purpose, De vennootschap heeft tot doel: de studie, het onderzoek, het ontwerp, de analyse, de beschouwing, de farmacodynamie, de productie, de vervaardiging, de promoti…
Corporate purpose, De vennootschap heeft tot doel, in België en in het buitenland, in eigen naam en voor eigen rekening: - Het aankopen, vervaardigen, verkopen van medisch materia…

31-05

NBB filing Annual accounts filed

fiscal year 2019 · full schema

2019

31-12

Financial Equity above €5MEq €9.36M ▲209%

2 profitable years in a row build equity to €9.36M.

26-11

State Gazette act Resignations & appointments

Board meeting · Director appointment2 facts ▸

Board meeting, 01/09/2019
Director appointment, Bart Ameije (persoon belast met het dagelijks bestuur)

16-10

State Gazette act Resignations & appointments

General meeting · Auditor appointment · Permanent representative3 facts ▸

General meeting, 24/06/2019
Auditor appointment, Deloitte Bedrijfsrevisoren CVBA (Commissaris)
Permanent representative, Ine Nuyts

05-06

State Gazette act Resignations & appointments

Board meeting · Director resignation · Director discharge3 facts ▸

Board meeting, 25/03/2019
Director resignation, Jumoo bvba (persoon belast met het dagelijks bestuur)
Director discharge, Jumoo bvba

23-05

NBB filing Annual accounts filed

fiscal year 2018 · full schema

2018

27-12

State Gazette act Resignations & appointments · Restructuring

Merger · Net-asset statement · Power of attorney5 facts ▸

Merger
Merger
Net-asset statement, 31/08/2018
Power of attorney, Tim DELAMEILLEURE
Power of attorney, Katja VAN DALSEN

17-10

State Gazette act Restructuring

Board meeting · Power of attorney · Merger7 facts ▸

Board meeting, 06/09/2018
Power of attorney, Tim Delameilleure
Power of attorney, Katja van Dalsen
Merger
Accounting effect, 01/09/2018
Corporate purpose, De vennootschap heeft tot doel: de studie, het onderzoek, het ontwerp, de analyse, de beschouwing, de farmacodynamie, de productie, de vervaardiging, de promoti…
Corporate purpose, De vennootschap heeft tot doel: groothandel van farmaceutische, parafarmaceutische en medische producten en aanverwante middelen. Zij mag alle mogelijke verrich…

17-10

State Gazette act Restructuring

Merger · Power of attorney · Accounting effect6 facts ▸

Merger
Power of attorney, Tim Delameilleure
Power of attorney, Katja van Dalsen
Accounting effect, 01/09/2018
Corporate purpose, De vennootschap heeft tot doel: de studie, het onderzoek, het ontwerp, de analyse, de beschouwing, de farmacodynamie, de productie, de vervaardiging, de promoti…
Corporate purpose, De vennootschap heeft tot doel: 1.Het produceren en ontwikkelen van cosmetica, dieetproducten, farmaceutische, scheikundige, parafarmaceutische en homeopatische…

10-07

State Gazette act Capital & shares · Statutes amendment

General meeting · Merger · Capital increase7 facts ▸

General meeting, 11/06/2018
Merger, absorption, 31/12/2017
Capital increase, €99.873,22
Capital increase, €859.098,16
Statutes amendment
Power of attorney, Tim DELAMEILLEURE
Power of attorney, Katja VAN DALSEN

23-05

NBB filing Annual accounts filed

fiscal year 2017 · full schema

24-04

State Gazette act Restructuring

Board meeting · Merger · Power of attorney17 facts ▸

Board meeting, 19/03/2018
Merger
Power of attorney, Tim Delameilleure
Power of attorney, Katja van Dalsen
Corporate purpose, De vennootschap heeft tot doel: De studie, het onderzoek, het ontwerp, de analyse, de beschouwing, de farmacodynamie, de productie, de vervaardiging, de promoti…
Corporate purpose, De Vennootschap heeft tot doel, zowel in België als in het buitenland zowel voor eigen naam en voor eigen rekening als voor naam of voor rekening van derden, al…
Net-asset statement, 31/12/2017
Net-asset statement, 31/12/2017
Share issue, 170.635
Accounting effect, 01/01/2018
Auditor appointment, PwC Bedrijfsrevisoren BCVBA
Auditor fee, 7.000, EUR
+5 further facts in this act

08-02

State Gazette act Resignations & appointments

General meeting · Board meeting · Director resignation7 facts ▸

General meeting, 04/12/2017
Board meeting, 04/12/2017
Director resignation, Johannes Stols (bestuurder)
Director discharge, Johannes Stols
Director appointment, Rafael Padilla (bestuurder)
Mandate compensation, Rafael Padilla
Director appointment, Cornelia de Jong (gedelegeerd bestuurder)

2017

04-12

State Gazette act Capital & shares · Miscellaneous

General meeting1 fact ▸

General meeting, 25/10/2017

30-11

State Gazette act Capital & shares

General meeting · Capital decrease · Statutes amendment4 facts ▸

General meeting, 31/10/2017
Capital decrease, €186.169.363,76
Statutes amendment
Power of attorney, Johan VERLINDEN

04-10

State Gazette act Resignations & appointments

General meeting · Director resignation · Director appointment6 facts ▸

General meeting, 28/08/2017
Director resignation, Kalman Petro (dagelijks bestuurder)
Director appointment, Jumoo bvba (dagelijks bestuurder)
Permanent representative, Daan Vermeulen
Mandate compensation, Jumoo bvba
Mandate limit, 100.000 EUR

26-07

State Gazette act Resignations & appointments

Board meeting · Director resignation2 facts ▸

Board meeting, 01/06/2017
Director resignation, Davy de Vlieger (dagelijks bestuurder)

31-05

State Gazette act Resignations & appointments

Board meeting · Director resignation · Director appointment11 facts ▸

Board meeting, 31/03/2017
Director resignation, Procuram bvba (dagelijks bestuurder)
Director resignation, Christophe Bouvry (dagelijks bestuurder)
Director resignation, Tim Delameilleure (dagelijks bestuurder)
Director appointment, Kalman Petro (dagelijks bestuurder)
Director appointment, Davy de Vlieger (dagelijks bestuurder)
Mandate compensation, Kalman Petro
Mandate compensation, Davy de Vlieger
Financial authorization, 500.000 EUR
Financial authorization, 100.000
Right of substitution, ja

09-05

NBB filing Annual accounts filed

fiscal year 2016 · full schema

26-04

State Gazette act Resignations & appointments

General meeting · Auditor appointment · Permanent representative4 facts ▸

General meeting, 30/06/2016
Auditor appointment, BCVBA PwC Bedrijfsrevisoren (commissaris)
Permanent representative, Peter Van den Eynde
Mandate term, na de algemene vergadering der aandeelhouders die de jaarekening per 31 december 2018 dient goed te keuren

2016

20-12

State Gazette act Resignations & appointments

General meeting · Director resignation · Director discharge9 facts ▸

General meeting, 17/10/2016
Director resignation, Jan Peeters nv (bestuurder)
Director discharge, Jan Peeters nv (bestuurder)
Director appointment, Cornelia de Jong (bestuurder)
Mandate compensation, Cornelia de Jong
Director appointment, Christophe Bouvry (persoon belast met het dagelijks bestuur)
Director appointment, Tim Delameilleure (persoon belast met het dagelijks bestuur)
Director resignation, Rony Lebotte (persoon belast met het dagelijks bestuur)
Financial limit, 1.000.000 EUR

22-11

State Gazette act Resignations & appointments

General meeting · Director appointment3 facts ▸

General meeting, 22/06/2016
Director appointment, Johan Verlinden (bestuurder)
Director appointment, Céline Caveye (bestuurder)

15-06

State Gazette act Miscellaneous

General meeting · Change of control2 facts ▸

General meeting, 30/05/2016
Change of control, wijziging van controle

10-05

State Gazette act Registered office

Board meeting · Registered-office move · Permanent representative3 facts ▸

Board meeting, 29/02/2016
Registered-office move, Venecoweg 20A, 9810 Nazareth
Permanent representative, Jan Peeters

23-03

State Gazette act Resignations & appointments

General meeting · Board meeting · Director resignation5 facts ▸

General meeting, 12/12/2015
Board meeting, 12/12/2015
Director resignation, Gerardus van Jeveren (bestuurder en gedelegeerd bestuurder)
Director appointment, Johannes Stols (bestuurder)
Director appointment, Johannes Stols (gedelegeerd bestuurder)

2015

04-02

State Gazette act Miscellaneous

General meeting · Change of control2 facts ▸

General meeting, 10/12/2014
Change of control, Wijziging van controle

2014

17-07

State Gazette act Resignations & appointments

Board meeting · Director resignation · Director discharge9 facts ▸

Board meeting, 25/04/2014
Director resignation, Romani Management BVBA (persoon belast met dagelijks bestuur)
Director discharge, Romani Management BVBA
Permanent representative, Filip Hoornaert
Director appointment, Procuram bvba (persoon belast met dagelijks bestuur)
Director appointment, Rony Lebotte (persoon belast met dagelijks bestuur)
Permanent representative, Michael Hillaert
Financial limit, 1.000.000 EUR
Financial limit, 1.000.000 EUR

21-05

State Gazette act Capital & shares

General meeting · Statutes amendment · Power of attorney3 facts ▸

General meeting, 11/04/2014
Statutes amendment
Power of attorney, Susana González Melón

05-05

State Gazette act Capital & shares · Resignations & appointments

General meeting · Capital increase · Statutes amendment4 facts ▸

General meeting, 25 maart 2014
Capital increase, €133.977.156
Statutes amendment
Power of attorney, Rony LEBOTTE

26-02

State Gazette act Resignations & appointments

Board meeting · Director appointment · Permanent representative6 facts ▸

Board meeting
Director appointment, Romani Management BVBA (persoon belast met dagelijks bestuur)
Director appointment, Rony Lebotte (persoon belast met dagelijks bestuur)
Permanent representative, Filip Hoornaert
Financial limit, 1000000 EUR
Financial limit, 1000000 EUR

06-02

State Gazette act Resignations & appointments

General meeting · Board meeting · Director reappointment6 facts ▸

General meeting, 14/05/2013
Board meeting, 14/05/2013
Director reappointment, Jan Peeters NV (bestuurder)
Director appointment, Gerardus Van Jeveren (bestuurder)
Director appointment, Jan Peeters NV (gedelegeerd bestuurder)
Permanent representative, Jan Peeters

06-02

State Gazette act Resignations & appointments

General meeting · Auditor appointment · Permanent representative4 facts ▸

General meeting, 14/05/2013
Auditor appointment, BCVBA PwC Bedrijfsrevisoren (commissaris)
Permanent representative, Peter Van den Eynde
Mandate term, na de algemene vergadering der aandeelhouders die de jaarrekening per 31 december 2015 dient goed te keuren

2012

03-07

State Gazette act Capital & shares

General meeting · Statutes amendment2 facts ▸

General meeting, 11 juni 2012
Statutes amendment

2011

20-04

State Gazette act Restructuring

General meeting · Merger · Name change5 facts ▸

General meeting, april 2011
Merger, met fusie door overneming gelijkgestelde verrichting
Name change, ACA PHARMA
Power of attorney, Ann DE SMEDT
Power of attorney, Rony LEBOTTE

24-02

State Gazette act Restructuring

Merger1 fact ▸

Merger, absorption

2010

21-12

State Gazette act Capital & shares

General meeting · Change of control2 facts ▸

General meeting, 06/12/2010
Change of control, true

22-09

State Gazette act Resignations & appointments

General meeting · Auditor appointment · Permanent representative4 facts ▸

General meeting, 11/05/2010
Auditor appointment, PricewaterhouseCoopers Bedrijfsrevisoren (commissaris)
Permanent representative, Peter Opsomer
Power of attorney, BV BVBA Peter Opsomer

02-03

State Gazette act Statutes amendment

General meeting · Capital · Corporate purpose4 facts ▸

General meeting, 12/02/2010
Capital, €52.892.207
Corporate purpose, De studie, het onderzoek, het ontwerp, de anałyse, de beschouwing, de farmacodynamie, de productie, de vervaardiging, de promotie, de verkoop, de handel, de ver…
Language change, van het Franse naar het Nederlandse taalgebied

12-01

State Gazette act Resignations & appointments · End & cessation

General meeting · Corporate decision · Statutes amendment3 facts ▸

General meeting, 22 décembre 2009
Corporate decision, Annulation de la décision de modifier la dénomination de la société prise le 14 octobre 2009
Statutes amendment

2009

09-11

State Gazette act Registered office · Resignations & appointments

General meeting · Name change · Registered-office move5 facts ▸

General meeting, 14 octobre 2009
Name change, ACA PHARMA
Registered-office move, 8790 Waregem, Textielstraat 24
Statutes amendment
Statutes amendment

2007

01-10

State Gazette act Assemblee Generale

General meeting1 fact ▸

General meeting, 20/09/2007

22-06

State Gazette act Resignations & appointments

General meeting · Auditor appointment2 facts ▸

General meeting, 30 mars 2007
Auditor appointment, SCCRL PricewaterhouseCoupers (réviseurs d'entreprises)

2006

02-01

State Gazette act Restructuring

Merger · Dissolution · Power of attorney5 facts ▸

Merger, 07/12/2005
Dissolution, 2005-12-07
Power of attorney, Rony LEBOTTE
Reference date, 30/06/2005
Shareholding, 100%

2005

10-10

State Gazette act Restructuring · Miscellaneous

Merger1 fact ▸

Merger, 26/09/2005

24-01

State Gazette act Capital & shares · Statutes amendment · Resignations & appointments

General meeting · Statutes amendment5 facts ▸

General meeting, 29/12/2004
Statutes amendment
Statutes amendment
Statutes amendment
Statutes amendment

Financial milestoneState Gazette actNBB filingFinancial milestones sit on the fiscal year-end date, not the filing date.

Directors · office · real estate

Directors

18 directors, no change since 2026

Padilla Rafael

Director · since 09-05-2023

Current

De Jong Cormelia Neeltje

Director · since 10-05-2022

Current

Céline Caveye

Director · since 01-07-2016

Current

JAN PEETERS

Director · since 14-05-2013 · Public limited company · perm. rep.: Jan Peeters

Not recently confirmed

01-04-2026 Johan Verlinden: Resigned as Director

09-05-2023 Padilla Rafael: Mandate renewed as Director

10-05-2022 De Jong Cormelia Neeltje: Mandate renewed as Director

12-05-2021 Céline Caveye: Appointed as Director

12-05-2021 Johan Verlinden: Appointed as Director

01-04-2021 Bart Ameije: Resigned as Director

01-03-2021 Hernando Acosta: Resigned as Director

01-10-2020 Hernando Acosta: Appointed as Persoon belast met het dagelijks bestuur

01-09-2019 Bart Ameije: Appointed as Persoon belast met het dagelijks bestuur

25-03-2019 Jumoo bvba: Resigned as Persoon belast met het dagelijks bestuur

04-12-2017 Johannes Stols: Resigned as Director

01-09-2017 Kalman Petro: Resigned as Daily management

01-06-2017 Davy De Vlieger: Resigned as Daily management

01-04-2017 Christophe Bouvry: Resigned as Daily management

01-04-2017 Procuram bvba: Resigned as Daily management

01-04-2017 Tim Delameilleure: Resigned as Daily management

17-10-2016 Jan Peeters NV: Resigned as Director

17-10-2016 Rony Lebotte: Resigned as Managing director

01-07-2016 Céline Caveye: Appointed as Director

01-07-2016 Johan Verlinden: Appointed as Director

12-12-2015 Gerardus van Jeveren: Resigned as Director

12-12-2015 Gerardus van Jeveren: Resigned as Managing director

25-04-2014 BVBA ROMANI MANAGEMENT: Resigned as Persoon belast met dagelijks bestuur

01-01-2014 Procuram bvba: Appointed as Persoon belast met dagelijks bestuur

+ 5 not shown in this overview

Location & real-estate footprint

Registered office, Nazareth-De Pinte · 1 establishment unit since 1992

establishment The establishment unit on the map

Cannot be placed on the map

This address could not be matched to a point in the Belgian address register (BOSA BEST). The address below comes straight from the Crossroads Bank.

Venecoweg 20A9810 Nazareth-De Pinte

Ground area

1.6 ha

Building footprint

7,285 m²

Volume, LiDAR

70,207 m³

Parcel 44048A0094/00L000, Flanders · tallest building 21.6 m, ±2 floors. Linked by address, not a title deed.

1 establishment unit

Infinity Pharma NV

Venecoweg 20A, 9810 Nazareth-De PinteAir transport

since 19922.013.193.230

1 parcel

Flanders 1 (100%)

Parcel (capakey)	Region	Area	Buildings	Height / fl.
44048A0094/00L000	Flanders	1.6 ha	1 · 7,284 m²	21.6 m · 2 fl.

Linked by address, not proof of ownership

Methodology

via registered seat: 1

1 of 1 parcel with an exact address match; the rest are indicative.

Linked through address data, this is not proof of ownership.

Statutory auditor

5 auditors

Deloitte Bedrijfsrevisoren/Réviseurs d’EntreprisesCurrent

Statutory auditor

16-10-2019 → present

Show 4 earlier auditors

PricewaterhouseCoopers Reviseurs d'Entreprises Statutory auditor · represented by Lien Winne succeeded by Deloitte Bedrijfsrevisoren/Réviseurs d’Entreprises in 2019	24-04-2018 → 16-10-2019
PricewaterhouseCoopers, Bedrijfsrevisoren Statutory auditor succeeded by PWC Bedrijfsrevisoren BCVBA in 2014	22-09-2010 → 06-02-2014
PWC Bedrijfsrevisoren BCVBA Statutory auditor · represented by Peter Van den Eynde succeeded by PricewaterhouseCoopers Reviseurs d'Entreprises in 2018	06-02-2014 → 24-04-2018
SCCRL PricewaterhouseCoupers Réviseurs d'entreprises · represented by Peter Opsomer succeeded by PricewaterhouseCoopers, Bedrijfsrevisoren in 2010	22-06-2007 → 22-09-2010